In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

My little theory is that the concept of “imprinting” in psychology can just as easily be applied to programming: Much as a baby goose decides that the first moving life-form it encounters is its ...

WASHINGTON — As part of next steps for the Janus Program, the Department of the Army has selected nine installations for consideration in which to site microreactor power plants, and the Defense ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

WASHINGTON — The Department of Army today announced the launch of the Janus Program, a next-generation nuclear power program that will deliver resilient, secure, and assured energy to support national ...

The deployment makes it possible for advertisers to execute video ad campaigns in a CTV-like manner using traditional TV ad inventory, the two companies said. When you purchase through links on our ...

Tracy J. Wholf is a senior coordinating producer of climate and environmental coverage for CBS News and Stations, based in New York. The Environmental Protection Agency announced Thursday it is ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...